Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.68 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.68 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135943 | 1.00 | PLA2G2A (0.68) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL9666963 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL2636226 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL15649018 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL9666571 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL25192254 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL15697666 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL7773487 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL543200 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A | |
| SCHEMBL9666565 | 0.98 | PLA2G2A (0.71) | PLA2G2APLA2G5FAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026098715-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-CLDN6 ANTIBODY | 智泽童康(广州)生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-122029199-A | Cysteine engineered antibodies and immunoconjugates | 信达生物制药(苏州)有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-111655295-B | Use of anti-HER 2 antibody drug conjugates in the treatment of urothelial cancer | 荣昌生物制药(烟台)股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117750980-A | Use of HER 2-targeted antibody-drug conjugates for the treatment of HER 2-underexpressed breast cancer | 荣昌生物制药(烟台)股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117615783-A | Use of antibody-drug conjugates in combination with immune checkpoint inhibitors for the treatment of urothelial cancer | 荣昌生物制药(烟台)股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117460538-A | Use of HER 2-targeting antibody-drug conjugates in the treatment of specific breast cancers | 荣昌生物制药(烟台)股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-116930494-A | Application of ICAM1 or coding gene thereof in preparation of cervical cancer treatment or diagnosis product | 浙江省肿瘤医院 | 2023-10-24 | — | — | CN | claimed |
| CN-116920112-A | Application of ICAM1 or coding gene thereof in preparation of gastric cancer treatment or diagnosis products | 浙江省肿瘤医院 | 2023-10-24 | — | — | CN | claimed |
| CN-116920113-A | Application of ICAM1 or coding gene thereof in preparation of cholangiocarcinoma treatment or diagnosis product | 浙江省肿瘤医院 | 2023-10-24 | — | — | CN | claimed |
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | claimed |
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| WO-2026098715-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-CLDN6 ANTIBODY | 智泽童康(广州)生物科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-122029199-A | Cysteine engineered antibodies and immunoconjugates | 信达生物制药(苏州)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |